stock-detail (KITE)

Oncology Corporate Profile

Brand Generic Indication
Yescarta™axicabtagene ciloleucelYescarta™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta™ is not indicated for the treatment of patients with primary central nervous system lymphoma
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
axicabtagene ciloleucelchimeric antigen receptor (CAR)®Diffuse large B-cell Lymphoma (DLBCL)II
KTE-C19chimeric antigen receptorMantle Cell Lymphoma (MCL)II
axicabtagene ciloleucelchimeric antigen receptor (CAR)®Primary mediastinal b-cell Lymphoma (PMBCL)II
axicabtagene ciloleucelchimeric antigen receptor (CAR)®Transformed follicular Lymphoma (TFL)II
KTE-C19chimeric antigen receptorAcute Lymphocytic Leukemia (ALL)I
KTE-C19chimeric antigen receptorB-cell LymphomaI
HPV-16 E6 & E7t-cell therapyCervical cancerINCI
KTE-C19chimeric antigen receptorDiffuse large B-cell Lymphoma (DLBCL)I
EGFRvIII CARchimeric antigen receptorGlioblastoma Multiforme (GBM)I
HPV-16 E6 & E7t-cell therapyHead & Neck cancerINCI
KTE-C19chimeric antigen receptor2nd line Diffuse large B-cell Lymphoma (DLBCL)Preclinical
KTE-C19chimeric antigen receptorAcute Myelogenous Leukemia (AML)Preclinical
KTE-C19chimeric antigen receptorChronic Lymphocytic Leukemia (CLL)Preclinical
KITE-585anti-B cell maturation antigen (BCMA) Multiple MyelomaPreclinical
KTE-C19chimeric antigen receptorNon-Hodgkin's Lymphoma (NHL)Preclinical
eACTt-cell therapyVarious cancer typesPreclinical

Recent News Headlines

8/21/2017 06:20 am

8/21/2017 06:20 am

8/21/2017 06:20 am

8/21/2017 06:20 am

8/21/2017 06:20 am

8/21/2017 12:20 am

8/21/2017 12:20 am

8/21/2017 12:20 am

8/21/2017 12:20 am

8/21/2017 12:20 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/16/2017 06:18 am

8/10/2017 06:18 am

8/9/2017 06:18 am

8/8/2017 06:18 am

8/7/2017 06:19 am

8/4/2017 06:18 am

8/3/2017 06:18 am

8/2/2017 06:32 am

8/2/2017 06:32 am

8/2/2017 06:32 am

8/2/2017 06:32 am